BNTX — BioNTech SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1776985 ·
Last close
$84.86
Market Cap
$21.32B
52W High
$124.00
52W Low
$79.52
ADV30
1,085,470
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,289,200,000 | 1,185,900,000 | 138,100,000 | 184,500,000 | 20,173,800,000 | 10,200,800,000 | 2,462,100,000 |
| Jun 2026 | 105,600,000 | 8,600,000 | -938,700,000 | -820,800,000 | 20,342,600,000 | 9,741,000,000 | 2,585,100,000 |
| Mar 2026 | 118,100,000 | 46,700,000 | -671,200,000 | -531,900,000 | 21,074,100,000 | 9,939,400,000 | 2,376,300,000 |
| Dec 2025 | 907,400,000 | 574,100,000 | -280,500,000 | -305,000,000 | 21,988,600,000 | 7,675,400,000 | 2,764,400,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-230,800,000
Investing CF
$632,600,000
Financing CF
$-329,000,000
CapEx
$-244,900,000
Dividends Paid
—
Buybacks
$-403,500,000
EPS Diluted TTM
$-5.86
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$16,793,700,000
Inventory
$64,900,000
Receivables
$796,000,000
ST Investments
$4,456,300,000
EBIT TTM
$-1,863,000,000
Pretax Income TTM
$-1,432,200,000
Interest Exp TTM
$21,900,000
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,649,999,872
EBITDA
$-1,380,800,000
Free Cash Flow
$-249,562,496
Enterprise Value
$11,151,198,208
Total Cash
$13,463,900,160
Total Debt
$316,100,000
Shares Out
251,204,366
Trailing EPS
$-7.81
Book Value
$82.23
ROE
-9.3%
ROA
-5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,869,900,000 | -640,700,000 | -1,136,100,000 | 21,988,600,000 | 2,764,400,000 | 19,224,200,000 | 456,000,000 |
| Dec 2024 | 2,751,100,000 | -709,400,000 | -665,300,000 | 22,529,700,000 | 3,118,600,000 | 19,411,100,000 | 207,700,000 |
| Dec 2023 | 3,819,000,000 | 875,600,000 | 930,300,000 | 23,006,300,000 | 2,760,400,000 | 20,245,900,000 | 5,371,400,000 |
| Dec 2022 | 17,310,600,000 | 12,303,800,000 | 9,434,400,000 | 23,279,100,000 | 3,223,500,000 | 20,055,600,000 | 13,577,400,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.69
Max Pain — expiry 2026-12-18
max pain strike: $110.00 · spot: $83.26 · call oi: 1,137 · put oi: 1,704
Expected Move to 2026-12-18:
±$7.90
(9.49%) —
implied range
$75.36 –
$91.16
· ATM straddle on $82.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.79B | $165.92 | — |
| EXEL | EXELIXIS, INC. | $16.71B | $68.50 | — |
| RVMD | Revolution Medicines, Inc. | $35.19B | $162.69 | — |
| BIIB | BIOGEN INC. | $37.07B | $250.79 | — |
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
News headlines (Yahoo Finance, 1h cache)
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
2026-11-13 16:17 · Yahoo
BioNTech (BNTX) Stock Looks Fully Valued As Sales Face Pressure
2026-11-13 12:11 · Yahoo
Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
2026-11-13 10:14 · Yahoo
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
2026-11-13 09:11 · Yahoo
Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
2026-11-12 21:29 · Yahoo
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
2026-11-12 16:53 · Yahoo
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
2026-11-06 16:05 · Yahoo
BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo
2026-11-04 03:18 · Yahoo
BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ...
2026-11-04 03:04 · Yahoo
Pfizer CEO Says Covid Is ‘Irrelevant.’ He’s Betting on Cancer and Weight-Loss Drugs.
2026-11-03 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.